glp 1/gip agonist New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight Mechanisms of action and therapeutic
Description
The intent of this change is not to compromise the integrity or safety of any sport where alcohol use is a concern, but rather to endorse a different means of enforcing bans on alcohol use in these sports
The SUPRPASS-4 trial (262), involving 2002 participants with high-risk cardiovascular profiles followed for up to 104 weeks, showed no difference in 4-MACE events (cardiovascular death, myocardial infarction, stroke, and hospitalization for unstable angina) with tirzepatide compared to insulin glargine (HR 0.74
This work was supported by the Lundbeck Foundation (fellowship R238-2016-2859), the BioInnovation Institute (grant number NNF20OC0063538) and the Novo Nordisk Foundation (grant numbers NNF17OC0026114 and NNF22OC0073778)
O.JohansenN
Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European Association for the Study of Obesity Physical Activity Working Group
Due to DPP-4 and renal clearance, native GLP-1 in humans has a half-life of about 1-2 minutes (89)
